{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T16:48:54Z","timestamp":1756572534008,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"name":"2seventy bio"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s12325-023-02623-w","type":"journal-article","created":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T08:02:38Z","timestamp":1692432158000},"page":"4626-4638","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed\/Refractory Multiple Myeloma in the KarMMa Trial"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4439-4788","authenticated-orcid":false,"given":"November","family":"McGarvey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Ung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Carattini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Imanak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy B.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pallavi","family":"Patwardhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,19]]},"reference":[{"issue":"5","key":"2623_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464\u201377. https:\/\/doi.org\/10.1001\/jama.2022.0003. (PMID: 35103762).","journal-title":"JAMA"},{"issue":"4","key":"2623_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/annonc\/mdx096","volume":"28","author":"P Moreau","year":"2017","unstructured":"Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(4):52\u201361. https:\/\/doi.org\/10.1093\/annonc\/mdx096. (PMID: 28453614).","journal-title":"Ann Oncol"},{"issue":"3","key":"2623_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"2623_CR4","unstructured":"National Cancer Institute: Surveillance Epidemiology and End Results Program. Cancer Statistics Explorer Network; Apr 19, 2023. [updated Jun 8, 2023]. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=89&data_type=9&graph_type=2&compareBy=rate_type&chk_rate_type_1=1&chk_rate_type_2=2&chk_rate_type_3=3&sex=1&race=1&age_range=1&hdn_stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#resultsRegion0. Accessed June 16, 2023."},{"issue":"2","key":"2623_CR5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.clml.2022.11.008","volume":"23","author":"HC Lee","year":"2023","unstructured":"Lee HC, Ramasamy K, Weisel K, et al. Treatment patterns, survival, quality of life, and healthcare resource use among patients with triple-class refractory multiple myeloma in US clinical practice: findings from the connect MM disease registry. Clin Lymphoma Myeloma Leuk. 2023;23(2):112\u201322. https:\/\/doi.org\/10.1016\/j.clml.2022.11.008. (PMID: 36567211).","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2623_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","volume":"78","author":"IS Nijhof","year":"2018","unstructured":"Nijhof IS, van de Donk N, Zweegman S, Lokhorst HM. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs. 2018;78:19\u201337. https:\/\/doi.org\/10.1007\/s40265-017-0841-y.","journal-title":"Drugs"},{"issue":"5","key":"2623_CR7","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/leu.2013.293","volume":"28","author":"H Ludwig","year":"2014","unstructured":"Ludwig H, Miguel JS, Dimopoulos MA, et al. International Myeloma Working Group recommendations for global myeloma care. Leukemia. 2014;28(5):981\u201392. https:\/\/doi.org\/10.1038\/leu.2013.293. (PMID: 24177258).","journal-title":"Leukemia"},{"issue":"11","key":"2623_CR8","doi-asserted-by":"publisher","first-page":"775","DOI":"10.2217\/fon-2022-1018","volume":"19","author":"P Hlavacek","year":"2023","unstructured":"Hlavacek P, Schepart A, Silverstein AR, Petrilla AA, Johnson W, Schroeder A. Medicare characteristics, treatment, cost and survival in triple class exposed relapsed or refractory multiple myeloma. Future Oncol. 2023;19(11):775\u201387. https:\/\/doi.org\/10.2217\/fon-2022-1018.","journal-title":"Future Oncol"},{"key":"2623_CR9","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266\u201375. https:\/\/doi.org\/10.1038\/s41375-019-0435-7.","journal-title":"Leukemia"},{"key":"2623_CR10","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/leu.2017.138","volume":"31","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Dimopoulos MA, Kastritis E, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31:2443\u20138. https:\/\/doi.org\/10.1038\/leu.2017.138.","journal-title":"Leukemia"},{"key":"2623_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clml.2019.09.621","volume":"20","author":"J Mikhael","year":"2020","unstructured":"Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20:1\u20137. https:\/\/doi.org\/10.1016\/j.clml.2019.09.621.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"2623_CR12","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/ejh.13426","volume":"105","author":"G Afram","year":"2020","unstructured":"Afram G, Gran C, Borg Bruchfeld J, et al. Impact of performance status on overall survival in patients with relapsed and\/or refractory multiple myeloma: real-life outcomes of daratumumab treatment. Eur J Haematol. 2020;105(2):196\u2013202. https:\/\/doi.org\/10.1111\/ejh.13426.","journal-title":"Eur J Haematol"},{"key":"2623_CR13","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.clml.2018.08.019","volume":"19","author":"N Despiegel","year":"2019","unstructured":"Despiegel N, Touboul C, Flinois A, et al. Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France. Clin Lymphoma Myeloma Leuk. 2019;19:e13-28. https:\/\/doi.org\/10.1016\/j.clml.2018.08.019.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2623_CR14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00520-020-05493-y","volume":"29","author":"M Kamal","year":"2021","unstructured":"Kamal M, Wang XS, Shi Q, et al. Symptom burden and its functional impact in patients with \u201csymptomatic\u201d relapsed or refractory multiple myeloma. Support Care Cancer. 2021;29:467\u201375. https:\/\/doi.org\/10.1007\/s00520-020-05493-y.","journal-title":"Support Care Cancer"},{"key":"2623_CR15","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s40487-021-00175-z","volume":"9","author":"S Jagannath","year":"2021","unstructured":"Jagannath S, Joseph N, He J, et al. Healthcare costs incurred by patients with multiple myeloma following triple class exposure (TCE) in the US. Oncol Ther. 2021;9:659\u201369. https:\/\/doi.org\/10.1007\/s40487-021-00175-z.","journal-title":"Oncol Ther"},{"key":"2623_CR16","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2217\/fon-2020-1003","volume":"17","author":"D Madduri","year":"2021","unstructured":"Madduri D, Hagiwara M, Parikh K, et al. Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA. Future Oncol. 2021;17:503\u201315. https:\/\/doi.org\/10.2217\/fon-2020-1003.","journal-title":"Future Oncol"},{"key":"2623_CR17","unstructured":"European Medicines - Medicines Agency. Abecma (idecabtagene vicleucel) [summary of product characteristics]. Dublin, Ireland: Bristol Myers Squibb Pharma EEIG. August 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/abecma-epar-product-information_en.pdf. Accessed June 16, 2023."},{"key":"2623_CR18","unstructured":"Bristol Myers Squibb. ABECMA (idecabtagene vicleucel). [Prescribing information]. https:\/\/packageinserts.bms.com\/pi\/pi_abecma.pdf. Accessed February 3. 2023."},{"key":"2623_CR19","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2024850.","journal-title":"N Engl J Med"},{"key":"2623_CR20","unstructured":"National Institutes of Health. ClinicalTrials.gov. Efficacy and safety study of bb2121 in subjects with relapsed and refractory multiple myeloma (KarMMa). [Published 3 Dec 2017]. [Updated 9 Mar 2023]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03361748. Accessed June 16, 2023."},{"key":"2623_CR21","unstructured":"Bristol Myers Squibb. Bristol-Myers Squibb and bluebird bio announce positive top-line results from the pivotal phase 2 KarMMa study of ide-cel in relapsed and refractory multiple myeloma [press release]; 2019. https:\/\/news.bms.com\/news\/corporate-financial\/2019\/Bristol-Myers-Squibb-and-bluebird-bio-Announce-Positive-Top-line-Results-from-the-Pivotal-Phase-2-KarMMa-Study-of-Ide-cel-in-Relapsed-and-Refractory-Multiple-Myeloma\/default.aspx. Accessed February 3, 2023."},{"issue":"Suppl 2","key":"2623_CR22","first-page":"S17","volume":"21","author":"LD Anderson","year":"2021","unstructured":"Anderson LD, Munshi NC, Shah N, et al. OAB-027: idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR-T cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa. Clin Lymphoma Myeloma Leuk. 2021;21(Suppl 2):S17\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2623_CR23","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1182\/bloodadvances.2021005913","volume":"6","author":"M Delforge","year":"2022","unstructured":"Delforge M, Shah N, Miguel JSF, et al. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma. Blood Adv. 2022;6:1309\u201318. https:\/\/doi.org\/10.1182\/bloodadvances.2021005913.","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"2623_CR24","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/j.jval.2021.04.150","volume":"24","author":"P Hari","year":"2021","unstructured":"Hari P, Nguyen A, Pelletier C, et al. PCN58 Estimation of post-infusion costs of care for patients with relapsed or refractory multiple myeloma (RRMM) who received idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa clinical trial. Value Health. 2021;24(Suppl 1):S29-30. https:\/\/doi.org\/10.1016\/j.jval.2021.04.150.","journal-title":"Value Health"},{"key":"2623_CR25","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2623_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13561-020-00298-5","volume":"11","author":"X Xu","year":"2021","unstructured":"Xu X, Lazar CM, Ruger JP. Micro-costing in health and medicine: a\u00a0critical appraisal. Health Econ Rev. 2021;11(1):1. https:\/\/doi.org\/10.1186\/s13561-020-00298-5. (PMID: 33404857; PMCID: PMC7789519).","journal-title":"Health Econ Rev"},{"key":"2623_CR27","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1097\/01.ccm.0000164543.14619.00","volume":"33","author":"JF Dasta","year":"2005","unstructured":"Dasta JF, McLaughlin TP, Mody SH, Piech CT. Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med. 2005;33:1266\u201371. https:\/\/doi.org\/10.1097\/01.ccm.0000164543.14619.00.","journal-title":"Crit Care Med"},{"key":"2623_CR28","unstructured":"Leavitt Partners. Cancer treatment costs are consistently lower in the community setting versus the hospital outpatient department [white paper]; 2017. https:\/\/leavittpartners.com\/whitepaper\/cancer-treatment-costs-are-consistently-lower-in-the-community-setting-versus-the-hospital-outpatient-department\/. Accessed February 3, 2023."},{"key":"2623_CR29","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/sj.bmt.1701191","volume":"21","author":"BR Meisenberg","year":"1998","unstructured":"Meisenberg BR, Ferran K, Hollenbach K, Brehm T, Jollon J, Piro LD. Reduced charges and costs associated with outpatient autologous stem cell transplantation. Bone Marrow Transplant. 1998;21:927\u201332. https:\/\/doi.org\/10.1038\/sj.bmt.1701191.","journal-title":"Bone Marrow Transplant"},{"key":"2623_CR30","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s40259-022-00557-3","volume":"36","author":"B Ghanem","year":"2022","unstructured":"Ghanem B, Shi L. The economic burden of CAR T cell therapies ciltacabtagene autoleucel and idecabtagene vicleucel for the treatment of adult patients with relapsed or refractory multiple myeloma in the US. BioDrugs. 2022;36:773\u201380. https:\/\/doi.org\/10.1007\/s40259-022-00557-3.","journal-title":"BioDrugs"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02623-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02623-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02623-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T05:14:50Z","timestamp":1694582090000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02623-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,19]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2623"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02623-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2023,8,19]]},"assertion":[{"value":"7 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"November McGarvey, Ken Imanak, and Abraham Lee are employees of BluePath Solutions, which received funding for this research from Bristol Myers Squibb. Thomas Carattini, Timothy B. Campbell, and Pallavi Patwardhan are employees and shareholders of Bristol Myers Squibb. Brian Ung was an employee of Bristol Myers Squibb at the time that the study was conducted and is now employed by Sarepta Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study does not contain any new analyses conducted by the authors with human participants or animals. The primary KarMMa study was conducted in accordance with the International Council for Harmonization guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki. The study protocol was approved by local or independent institutional review boards or ethics committees at participating sites. All the patients provided written informed consent. The authors had permission to access and use the clinical trial database for this study. The efficacy and safety data from the KarMMa clinical trial along with the patient reported outcomes have been previously published [, , ].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}